Enlivex Therapeutics Ltd.
ENLV | NASDAQ
$1.29
-$0.10 (-7.19%)
At close: Nov 5, 2026, 3:59 PM ET
$1.35
+$0.06 (+4.65%)
After-hours:
Nov 5, 2026, 5:16 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | 0.03 | -1.60 | -1.73 | -1.71 | -11.57 | -8.03 |
PEG Ratio | 0 | 0.03 | 0.05 | -0.01 | 0.24 | 0.78 |
PS Ratio | n/a | n/a | n/a | n/a | n/a | 48.76 |
PB Ratio | 0.02 | 1.02 | 1.67 | 1.28 | 1.31 | 3.13 |
P/FCF Ratio | -3.07 | -1.83 | -2.11 | -2.26 | -5.82 | -9.23 |
P/OCF Ratio | -3.09 | -1.85 | -2.13 | -3.03 | -6.36 | -10.09 |
OCF/S Ratio | n/a | n/a | n/a | n/a | n/a | -483.40 |
Debt / Equity Ratio | 0 | 0.02 | 0.03 | 0.09 | 0.07 | 0.01 |
Quick Ratio | 193.24 | 6.84 | 5.57 | 7.74 | 18.32 | 8.72 |
Current Ratio | 193.24 | 6.84 | 5.57 | 7.92 | 18.32 | 8.72 |
Asset Turnover | n/a | n/a | n/a | n/a | n/a | 0.06 |
Interest Coverage | -1.15K | -1.2K | -2.1K | -4.90 | -58.80 | -1.63K |
Return on Equity | 63.85% | -63.65% | -96.62% | -54.64% | -17.01% | -33.32% |
Return on Assets | 53.10% | -54.23% | -78.92% | -45.92% | -15.21% | -29.30% |
Return on Invested Capital | -0.49% | -64.40% | -94.47% | -41.82% | -21.19% | -27.04% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | n/a | n/a | n/a | -12.56% |
Net Profit Margin | n/a | n/a | n/a | n/a | n/a | -519.28% |
Pretax Profit Margin | n/a | n/a | n/a | n/a | n/a | -519.28% |
Operating Profit Margin | n/a | n/a | n/a | n/a | n/a | -429.73% |
FCF Margin | n/a | n/a | n/a | n/a | n/a | -528.15% |
EBITDA Margin | n/a | n/a | n/a | n/a | n/a | -417.17% |
Add to Watchlist
Select watchlists to add or remove ENLV